BioPAL specializes in a new generation of high-precision alternatives to traditional, radiolabeled life science products.  Our products are labeled with stable (non-radioactive) isotopes.  BioPAL specializes in the development of products for applications using neutron activation (NA), magnetic resonance imaging (MRI), functional immunoassay technology (FIT), time resolved fluorescence (TRF), and electron microscopy (EM) technologies.

This section is devoted to highlight current developments at BioPAL, such as the announcement of scientific research agreements, company milestones, and general news of interest to the biomedical research community.

Publications:
In vivo tracking of cells using a multi-detection probe. Int Soc for Stem Cell Res, 2^nd Annual Meeting 2004, Abstract 233.

Quantitative in vivo tracking of labeled cells using a non-radioactive, non-optical technology. Stem Cells, Keystone Symposia 2004, Abstract 431.

Method to quantify tail vein injection technique in small animals. Contemporary Topics Lab Ani Sci 2004; 43:35-38.

Neutron-activation analysis: A novel method for the assay of iohexol. J Lab Clin Med 2003; 141:106-109.

Damage to the protein synthesizing apparatus in mouse liver in vivo by magnetocytolysis in the presence of hepatospecific magnetic nanoparticles. J Magn Magn Mater 2002; 248:276-285.

Stable labeled microspheres to measure perfusion: validation of a neutron activation assay technique. Am J Physiol Heart Circ Physiol 2001; 280:H108-H116.

Hepatocyte asialoglycoprotein receptor assay using stable isotopes and neutron activation analysis. Clin Chem 2000; 46:1519-1521.

Grants:
BioPAL is grateful for the grant support it has received from the NIH for the development of new technologies to measure organ function and the development of new diagnostics and therapies. Our technologies will play major roles in physiology research, systems biology and clinical diagnosis.

Phase I (1 R43 DK078404) Glomerular filtration rate test

Fast-Track - Phase I & II (1 R44 HL080837) Magnetic resonance angiography

Phase I (1 R43 RR020235) An Accelerator-based neutron activation device

Phase I (1 R43 AI063731) Multi-labeled material for in vivo cell tracking

Phase I & II (2 R44 HL073472; 1 R43 HL073472) Method to evaluate and quantify myocardial injections

Phase I & II (1 R43 DK57502; 2 R44 DK057502) Novel method to measure glomerular filtration rate

Phase I (1 R43 AT01390) Chromium analysis and diabetes

Phase 1 (1 R43 DK58434) Hepatocyte asialoglycoprotein receptor assay

Phase 1 (1 R43 DK57972) Novel method to measure bile acid transport

Phase 1 (1 R43 DK56521) Novel method to measure glomerular size-selectivity

Phase I & II (1 R43 HL60403; 5 R44 HL60403)    Non-radioactive method to measure organ blood flow

New Products:
BioPAL introduces functional immunoassay technology (FIT^TM) and develops a FIT-based GFR kit.

MRI contrast agents including a unique and novel colloidal gadolinium reagent.  BioPAL is the only company focused on developing new MRI contrast agents for drug discovery and research.

IVST multidetection materials for both quantification and imaging of cells in cellular therapy

CELLTrack™ colloidal materials for quantification of cells for cellular therapies

RenalRate™ for the non-radioactive measurement of glomerular filtration rate. Multiple labels are available.

PROTrack™ for nonradioactive labeling of proteins

AccuJECT™ for validation of injection. This technology is especially important for drug discovery.

Time-Resolved Fluorescence Technology for the best in fluorescence labeling

Patents:
BioPAL has applied for patents across a range of biophysical technologies including neutron activation, MRI, fluorescence and nanomaterials. Please contact us for licensing opportunities.

Patent Number: 6,328,700 — Locating marker/tracer elements detectable by neutron activated analysis within or on carrier microspheres, including microspheres used in biological experimentation.

Press Releases:
January, 2006 — BioPAL announces the development of Functional Immunoassay Technology (FIT).  BioPAL is developing a panel of renal diagnostics using the FIT format, which includes methods to measure glomerular filtration rate (GFR), effective renal plasma flow (ERPF), and the renal filtration fraction (FF).

August, 2005 — BioPAL announces the development of the first stable, ultra-small gadolinium colloid for MRI applications.

July, 2004 — BioPAL develops new state-of-the-art equipment to provide increased capacity for high sensitivity assays.

Upcoming Meetings:
November, 2007 — BioPAL will be attending the 2007 scientific meeting of the American Society of Nephrology in San Francisco.  Our booth number is 1622.  Results from two clinical trials using our FIT-GFR test kit will be presented.